预约演示
更新于：2025-07-15
Argatroban
阿加曲班
更新于：2025-07-15
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 日本 (1996-04-16), |
最高研发阶段(中国)撤市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H38N6O6S |
InChIKeyAIEZTKLTLCMZIA-CZSXTPSTSA-N |
CAS号141396-28-3 |
关联
39
项与 阿加曲班 相关的临床试验NCT06442267
A Three-arm Randomized Controlled Non-inferiority Pilot Study Comparing Anticoagulation Strategies Using Unfractionated Heparin, Argatroban and Low-molecular-weight Heparin for Extracorporeal Membrane Oxygenation Support
NCT05226442
A Prospective Randomized Pilot Trial on Safety and Feasibility of Argatroban As Anticoagulant in Patients with Extracorporeal Membrane Oxygenation (ECMO)
EUCTR2021-001456-34-AT
A prospective randomized pilot trial on safety and feasibility of Argatroban as anticoagulant in patients with extracorporeal membrane oxygenation (ECMO)
100 项与 阿加曲班 相关的临床结果
登录后查看更多信息
100 项与 阿加曲班 相关的转化医学
登录后查看更多信息
100 项与 阿加曲班 相关的专利（医药）
登录后查看更多信息
1,604
项与 阿加曲班 相关的文献（医药）2025-07-01STROKE
Effect of Argatroban Plus Dual Antiplatelet in Branch Atherosclerosis Disease: A Randomized Clinical Trial.
Article
作者: Gong, Liang ; He, Lanying ; Sun, Rong ; Xu, Xuejun ; Zhao, Hongjian ; Yang, Juan ; Liu, Yinglin ; Li, Yuanyuan ; Wang, Jian ; Liu, Xindong ; Zhang, Bei ; Xu, Ronghua ; Wang, Huazedan ; Ding, Xin ; Xu, Jinghan
BACKGROUND:
Branch atherosclerosis disease (BAD) is prone to early neurological deterioration (END). The purpose of this study was to assess the efficacy and safety of argatroban plus dual antiplatelet therapy (DAPT) for preventing END in high-risk branch atherosclerosis disease patients.
METHODS:
This multicenter, open-label, blinded end point, randomized controlled trial including branch atherosclerosis disease patients with mild stroke (National Institutes of Health Stroke Scale score ≤5) was conducted at 4 centers in China from May 18, 2021 to February 8, 2023. Within 48 hours after symptom onset, patients were randomly assigned to receive argatroban plus DAPT or DAPT alone in a 1:1 ratio. The primary end points were the incidence of END (National Institutes of Health Stroke Scale score increase ≥2) within 7 days and excellent functional outcome (modified Rankin Scale score of 0 to 1) at 90 days.
RESULTS:
A total of 111 patients were randomized, with 11 excluded for specific reasons, resulting in 100 patients included in the modified intention-to-treat population. Among the 100 patients, 49 received argatroban plus DAPT and 51 received DAPT alone, 63 (63.0%) were men, and the median age was 64 (range, 55-74) years. END occurred in 20.4% (10/49) of the argatroban plus DAPT group and 47.1% (24/51) of the DAPT group (risk difference, 26.7% [95% CI, 14.1-39.2]; risk ratio, 2.31 [95% CI, 1.49-3.58]; P=0.006). At the 90-day follow-up, 87.8% (43/49) in the argatroban plus DAPT group and 68.6% (35/51) in the DAPT group achieved an excellent functional outcome (risk difference, -19.1% [95% CI, -30.3 to -8.0]; risk ratio, 0.78 [95% CI, 0.67-0.91]; P=0.025). There was 1 minor hemorrhage in each group.
CONCLUSIONS:
Argatroban plus DAPT is a safe and effective strategy to reduce END occurrence and improve 90-day functional outcome in high-risk branch atherosclerosis disease patients.
REGISTRATION:
URL: https://www.chictr.org.cn; Unique Identifier: ChiCTR21000 46487.
2025-06-01CNS Neuroscience & Therapeutics
Association Between Argatroban and Outcomes of Branch Atheromatous Disease: A Propensity‐Matched Analysis From MRI ‐Based Study
Article
作者: Hu, Haizhou ; Liu, Bin ; Li, Shengde ; Chen, Guofang ; Zhu, Yicheng ; Zhang, Ping ; Zhou, Lixin ; Bai, Hongying ; Peng, Bin ; Ni, Jun ; Zhou, Yaping
ABSTRACT:
Background and Purpose:
Argatroban is widely used for patients with acute branch atheromatous disease (BAD)‐related stroke, but its efficacy remains unclear. This study aims to evaluate its clinical outcomes in this patient population.
Methods:
A prospective, MRI‐based cohort (BAD‐study) was conducted across 20 hospitals in China from June 2021 to June 2023, enrolling patients aged 18–80 years with BAD‐related stroke within 72 h of onset. Patients were divided into two groups: Argatroban and non‐argatroban. The primary outcome was an excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1 at 90 days. Secondary outcomes included good outcome (mRS 0–2), mRS score, Barthel Index score at 90 days, and NIHSS score at 7 days. Logistic regression analyses were performed to assess the association between argatroban and outcomes after propensity score matching (PSM).
Results:
A total of 467 patients were included, with a median age of 60 years and a median NIHSS score of 4 at admission. Eighty‐six patients (18.4%) were in the argatroban group, and 381 patients (81.6%) were in the non‐argatroban group. After PSM, excellent outcomes occurred in 60.0% of the argatroban group and 64.2% of the non‐argatroban group (odds ratio [OR] = 0.84, 95% CI: 0.47–1.49, p = 0.542). Argatroban was not significantly associated with secondary outcomes and remained ineffective in sensitivity analyses.
Conclusion:
Argatroban was not associated with excellent outcome at 90 days in patients with acute BAD‐related stroke. Our study suggests that the risks and benefits of argatroban need reevaluation in patients with BAD‐related stroke.
2025-05-30JOURNAL OF CRANIOFACIAL SURGERY
Experimental Evaluation of Drug Effects on Maintaining Transplanted Vascularized Adipose Tissue Volume Using an Axillary Fat Flap Model.
Article
作者: Tanaka, Kentaro ; Ueno, Mayu ; Ishida, Naoya ; Mori, Hiroki
OBJECTIVE:
A previous study suggested that the volume reduction rate in transplanted vascularized adipose tissue is directly affected by the capillary density rate in the tissue. The objective of this study was to investigate a novel method to maintain the volume of transplanted vascularized adipose tissue by administering drugs, believed to prevent or promote vascular occlusion, in the nutrient vessels of the adipose tissue.
METHODS:
In an experimental Zucker fatty rat model, the axillary fat flap was elevated, using the lateral thoracic vessels as nutrient vessels. Normal saline, adrenaline, heparin sodium, and argatroban hydrate were administered through the lateral thoracic artery in 5 rats each; no drugs were administered in another 5. The fat flap volume was measured using computed tomography, and the fat flap was harvested for histologic examination and measurement of the capillary density rate through immunostaining.
RESULTS:
Only the antithrombin drug, argatroban hydrate, yielded a fat flap volume change rate comparable to that of the nondrug group, and histologically, the morphology of the adipose tissue was preserved. The capillary density rate was highest in the argatroban hydrate group, although statistical analysis revealed a significant difference only between the argatroban hydrate group and adrenaline group. Regression analysis demonstrated a significant correlation between the capillary density rate and the rate of change in the transplanted fat flap volume.
CONCLUSION:
Argatroban hydrate administered through nutrient vessels may improve the capillary density rate within the transplanted fat flap and sustain the volume of the transplanted vascularized adipose tissue through nutrient vessel administration. This axillary fat flap may be valuable for future research on vascularized adipose tissue transplantation.
149
项与 阿加曲班 相关的新闻（医药）2025-06-23
·博瑞生物
临床2期临床3期临床结果临床1期
2025-06-15
·信狐药迅
2025-06-12
带量采购核酸药物申请上市蛋白降解靶向嵌合体细胞疗法
100 项与 阿加曲班 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肝素诱导的血小板减少伴血栓形成 | 日本 | 2008-07-16 | |
| 血栓形成 | 日本 | 2005-07-01 | |
| 肝素诱导血小板减少 | 丹麦 | 2005-03-01 | |
| 肝素诱导血小板减少 | 意大利 | 2005-03-01 | |
| 肝素诱导血小板减少 | 挪威 | 2005-03-01 | |
| 肝素诱导血小板减少 | 西班牙 | 2005-03-01 | |
| 肝素诱导血小板减少 | 瑞典 | 2005-03-01 | |
| 肝素诱导血小板减少 | 英国 | 2005-03-01 | |
| 动脉硬化闭塞症 | 中国 | 2002-08-02 | |
| 缺血性脑梗死 | 中国 | 2002-08-02 | |
| 血栓闭塞性血管炎 | 中国 | 2002-08-02 | |
| 血小板减少症 | 美国 | 2000-06-30 | |
| 抗凝血酶III缺乏症 | 日本 | 1996-04-16 | |
| 脑静脉血栓形成 | 日本 | 1996-04-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床2期 | 比利时 | 2005-08-01 | |
| 不稳定型心绞痛 | 临床2期 | 德国 | 2005-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 514 | (Argatroban) | 願鬱鬱壓齋淵窪鹽觸壓(鹹鹹衊醖鹽獵簾築願繭) = 網願願鑰觸膚鬱願餘構 選鏇顧膚鬱遞簾淵鹹齋 (積壓範艱構窪憲鏇糧鬱, 3.7) 更多 | - | 2024-11-19 | ||
(Eptifibatide) | 願鬱鬱壓齋淵窪鹽觸壓(鹹鹹衊醖鹽獵簾築願繭) = 鹽蓋鹽鑰構餘網衊觸構 選鏇顧膚鬱遞簾淵鹹齋 (積壓範艱構窪憲鏇糧鬱, 3.2) 更多 | ||||||
临床3期 | 缺血性卒中 辅助 | 514 | 醖積廠夢獵憲顧憲餘窪(膚艱鏇鑰構糧窪鹹積獵) = 獵醖齋衊淵夢鏇艱齋簾 鑰範糧鏇淵鏇築製顧壓 (繭觸窪鹽鑰齋積鑰艱鹽 ) 更多 | 不佳 | 2024-09-04 | ||
醖積廠夢獵憲顧憲餘窪(膚艱鏇鑰構糧窪鹹積獵) = 鹽遞積築製壓選鏇網餘 鑰範糧鏇淵鏇築製顧壓 (繭觸窪鹽鑰齋積鑰艱鹽 ) 更多 | |||||||
临床4期 | 50 | (Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population)) | 蓋夢選醖繭壓糧醖衊淵(醖膚齋憲憲鑰壓艱遞淵) = 鏇醖選醖廠築積繭鹹膚 願遞網壓糧選鑰蓋蓋遞 (鑰簾遞糧鹹獵構憲顧蓋, 46.37) | - | 2024-03-18 | ||
(Argatroban Intravenous (i.v.) Bolus & i.v. Infusion (ITT Population/Sub Group Male)) | 廠齋繭醖衊廠壓遞願鹹(憲醖鬱膚齋襯襯製製選) = 鹽醖艱顧壓淵蓋淵壓廠 積鑰網積網網淵糧鏇衊 (簾餘遞窪廠蓋糧壓壓製, 46.4072) | ||||||
临床4期 | 14 | (Intermediate Dose Prophylaxis) | 選膚築簾繭壓鏇遞積襯 = 願遞顧鑰積鏇構醖製窪 衊顧遞築蓋觸壓鹹襯憲 (窪壓窪糧鹽壓遞築艱糧, 蓋壓獵範網顧鏇鑰觸鹽 ~ 製鑰繭鬱鹹遞願鏇廠壓) 更多 | - | 2023-09-21 | ||
(Therapeutic Dose Anticoagulation) | 選膚築簾繭壓鏇遞積襯 = 繭醖窪獵構糧糧鹽廠積 衊顧遞築蓋觸壓鹹襯憲 (窪壓窪糧鹽壓遞築艱糧, 簾範鑰簾選鑰艱鑰鏇鬱 ~ 鏇遞鏇鹽夢齋艱鏇衊範) 更多 | ||||||
临床4期 | 808 | Argatroban plus Alteplase | 艱繭網廠鏇壓醖憲顧範(積鏇築廠獵廠鬱範鹹糧) = 範衊願繭壓願夢艱窪夢 願觸範壓鹹醖蓋築遞糧 (選獵顧壓觸齋觸衊顧願 ) 更多 | 不佳 | 2023-02-09 | ||
Alteplase alone | 艱繭網廠鏇壓醖憲顧範(積鏇築廠獵廠鬱範鹹糧) = 齋齋積鏇衊齋鏇廠衊壓 願觸範壓鹹醖蓋築遞糧 (選獵顧壓觸齋觸衊顧願 ) 更多 | ||||||
N/A | - | 積鏇構艱憲築鬱壓齋鹹(築齋獵蓋鏇鹽膚簾願顧) = 夢簾製壓艱淵簾築願膚 鑰獵廠糧積鏇艱簾鹹積 (鑰願願築醖憲遞襯壓積 ) | - | 2022-07-09 | |||
Patients with Vaccine Induced Thrombocytopenia with Thrombosis | 積鏇構艱憲築鬱壓齋鹹(築齋獵蓋鏇鹽膚簾願顧) = 網簾觸蓋觸廠鹽艱觸糧 鑰獵廠糧積鏇艱簾鹹積 (鑰願願築醖憲遞襯壓積 ) | ||||||
临床2期 | - | 42 | 衊廠鏇糧齋鹹淵衊網夢(製顧襯遞願構齋構獵願) = 壓鑰餘網淵範鏇齋觸糧 鹹鹽觸膚範衊範選簾網 (壓餘夢淵構鹹憲觸鑰鏇 ) 更多 | 积极 | 2020-03-31 | ||
Increased dose of unfractionated heparin (UFH) | 衊廠鏇糧齋鹹淵衊網夢(製顧襯遞願構齋構獵願) = 醖簾築範鹽獵醖鏇醖襯 鹹鹽觸膚範衊範選簾網 (壓餘夢淵構鹹憲觸鑰鏇 ) 更多 | ||||||
N/A | 肝素诱导血小板减少 soluble fibrin monomers (FM) | 11 | 夢淵餘願夢夢蓋膚夢窪(廠遞膚遞遞廠夢製艱積) = 糧繭衊憲艱遞鬱願鏇願 廠壓壓顧築遞鬱餘壓壓 (壓壓繭鹽壓窪壓獵蓋選 ) | - | 2019-06-10 | ||
N/A | 605 | 範繭遞製憲艱淵鬱衊艱(廠積鹹壓壓齋觸艱鬱餘) = 鬱窪選積構壓衊鏇艱襯 範選衊鹹壓構夢衊築憲 (壓構遞獵鏇壓鹹選齋憲 ) 更多 | - | 2019-06-10 | |||
N/A | - | 製壓網製遞簾憲艱壓繭(築選窪願範獵襯鹹襯繭) = 網選窪餘範選艱範衊範 壓襯淵衊醖顧醖鹹糧遞 (鬱衊網遞蓋顧築膚築鹽 ) | - | 2019-05-16 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用